Insulin glargine and lixisenatide Subcutaneous and NovoLog Mix 70/30
Determining the interaction of Insulin glargine and lixisenatide Subcutaneous and NovoLog Mix 70/30 and the possibility of their joint administration.
No interaction was detected between the selected drugs or effects of joint drug administration are currently understudied, and it takes time and accumulated statistics to determine their interaction. A doctor should be consulted to address the issue of joint drug administration.
Generic Name: insulin glargine / lixisenatide
Brand name: Soliqua 100/33
Synonyms: Insulin glargine and lixisenatide (Subcutaneous)
Generic Name: insulin aspart / insulin aspart protamine
Brand name: NovoLog Mix 70/30, NovoLog Mix 70/30 FlexPen, NovoLOG Mix 70/30 PenFill
Synonyms: n.a.
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Insulin glargine and lixisenatide Subcutaneous-NovoLog Mix 70/30 (Insulin Aspart Protamine and Insulin Aspart (Cartridges and Prefilled Pens))
- Insulin glargine and lixisenatide Subcutaneous-NovoLog Mix 70/30 (Insulin Aspart Protamine and Insulin Aspart (Vials))
- Insulin glargine and lixisenatide Subcutaneous-NovoLog Mix 70/30 FlexPen
- Insulin glargine and lixisenatide Subcutaneous-NovoLog PenFill
- Insulin glargine and lixisenatide Subcutaneous-Novoseven
- Insulin glargine and lixisenatide Subcutaneous-NovoSeven RT
- NovoLog Mix 70/30-Insulin glargine, recombinant Subcutaneous
- NovoLog Mix 70/30-Insulin glulisine
- NovoLog Mix 70/30-Insulin Glulisine (Cartridges and Pens)
- NovoLog Mix 70/30-Insulin Glulisine (Vials)
- NovoLog Mix 70/30-Insulin glulisine Subcutaneous
- NovoLog Mix 70/30-Insulin human inhaled Inhalation